Diligence memo · auto-generated · as of July 2, 2026
Arialys Therapeutics, Inc.
Arialys Therapeutics, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Arialys Therapeutics, Inc. operates in Biotechnology, based in LA JOLLA.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Arialys Therapeutics, Inc. has raised $29M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $15M on 2025-06-13.
Most recent recorded round closed around 2025-06-13.
Valuation (modeled)modeled
Provath models Arialys Therapeutics, Inc. at approximately $49M (range $16M–$85M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.14× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 31 months.
Last raise 13 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 74% of Biotechnology peers (4293 compared).
Modeled value ranks above 45% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Nuclein, LLC, Phantom Neuro Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.